Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1202-1210

  Albertí, Joan ^a   Martinet, Audrey ^a,b   Sentellas, Sònia ^a   Salvà, Miquel ^a  

^a Department of Pharmacokinetics and Drug Metabolism Almirall SA ^*  (Spain)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ACLIDINIUM BROMIDE; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CARBOXYLESTERASE; CHOLINESTERASE; CYTOCHROME P450; SERUM ALBUMIN; ENZYME INHIBITOR; ESTERASE; ISOENZYME; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG; NORMAL HUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; HYDROLYSIS; MALE; METABOLISM;

ANIMALIA;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ESTERASES; FEMALE; HUMANS; HYDROLYSIS; IN VITRO TECHNIQUES; ISOENZYMES; MALE; MUSCARINIC ANTAGONISTS; SERUM ALBUMIN; TROPANES;

EID: 77953785085     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.031724     Document Type: Article

References (40)

1. Akizuki S, Ohnishi A, Kotani K, and Sudo K (2004) Genetic and immunological analyses of patients with increased serum butyrylcholinesterase activity and its C5 variant form. Clin Chem Lab Med 42:991-996.
2. Aldridge WN (1953) Serum esterases. I. Two types of esterase (A and B) hydrolysing pnitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J 53:110-117.
3. Altamirano CV, Bartels CF, and Lockridge O (2000) The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme. J Neurochem 74:869-877.
4. Bartels CF, James K, and La Du BN (1992) DNA mutations associated with the human butyrylcholinesterase J-variant. Am J Hum Genet 50:1104-1114.
5. Bodur E, Cokuǧraş AN, and Tezcan EF (2001) Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase. Arch Biochem Biophys 386:25-29.
6. Brimijoin S and Hammond P (1988) Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay. J Neurochem 51:1227-1231.
7. Chapuis N, Brühlmann C, Reist M, Carrupt PA, Mayer JM, and Testa B (2001) The esterase-like activity of serum albumin may be due to cholinesterase contamination. Pharm Res 18:1435-1439.
8. Chatonnet A and Lockridge O (1989) Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 260:625-634.
9. Ellman GL, Courtney KD, Andres V Jr, and Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
10. Gavaldà A, Miralpeix M, Ramos I, Otal R, Carreňo C, Viňals M, Doménech T, Carcasona C, Reyes B, Vilella D, et al. (2009) Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 331:740-751.
11. Guengerich FP (1987) Oxidative cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 262:8459-8462.
12. Harris H and Whittaker M (1961) Differential inhibition of human serum cholinesterase with fluoride: recognition of two new phenotypes. Nature 191:496-498.
13. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
14. Jansat JM, Lamarca R, Garcia Gil E, and Ferrer P (2009) Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 47:460-468.
15. Jbilo O, Bartels CF, Chatonnet A, Toutant JP, and Lockridge O (1994) Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 32:1445-1457.
16. Jewell C, Bennett P, Mutch E, Ackermann C, and Williams FM (2007) Inter-individual variability in esterases in human liver. Biochem Pharmacol 74:932-939.
17. Krause A, Lane AB, and Jenkins T (1988) A new high activity plasma cholinesterase variant. J Med Genet 25:677-681.
18. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, and Lockridge O (2005) Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673-1684.
19. Lockridge O (1990) Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 47:35-60.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Mackness B, Durrington PN, and Mackness MI (1998) Human serum paraoxonase. Gen Pharmacol 31:329-336.
22. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O, and La Du BN (1989) Identification of the structural mutation responsible for the dibucaineresistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA 86:953-957.
23. Müller TC, Rocha JB, Morsch VM, Neis RT, and Schetinger MR (2002) Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. Biochim Biophys Acta 1587:92-98.
24. Nogueira CP, Bartels CF, McGuire MC, Adkins S, Lubrano T, Rubinstein HM, Lightstone H, Van der Spek AF, Lockridge O, and La Du BN (1992) Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. Am J Hum Genet 51:821-828.
25. Nogueira CP, McGuire MC, Graeser C, Bartels CF, Arpagaus M, Van der Spek AF, Lightstone H, Lockridge O, and La Du BN (1990) Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT - GGAG). Am J Hum Genet 46:934-942. (Pubitemid 20164354)
26. Peng HM, Raner GM, Vaz AD, and Coon MJ (1995) Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450. Arch Biochem Biophys 318:333-339.
27. Prat M, Fernández D, Buil MA, Crespo MI, Casals G, Ferrer M, Tort L, Castro J, Monleón JM, Gavaldà A, et al. (2009) Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy (di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J Med Chem 52:5076-5092.
28. Rodrigo L, Mackness B, Durrington PN, Hernandez A, and Mackness MI (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 354:1-7.
29. Ryhänen RJ (1983) Pseudocholinesterase activity in some human body fluids. Gen Pharmacol 14:459-460. (Pubitemid 13030392)
30. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
31. Schwarz M, Glick D, Loewenstein Y, and Soreq H (1995) Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol Ther 67:283-322.
32. Sentellas S, Ramos I, Albertí J, Salvà M, Antón F, Miralpeix M, Beleta J, and Gavaldà A (2010) Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 39:283-290.
33. Sípal Z, Ahlenius T, Bergstrand A, Rodriquez L, and Jakobsson SW (1979) Oxidative biotransformation of benzo(a)pyrene by human lung microsomal fractions prepared from surgical specimens. Xenobiotica 9:633-645. (Pubitemid 10167102)
34. Sohlenius-Sternbeck AK (2006) Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol In Vitro 20:1582-1586.
35. Sudo K, Maekawa M, Akizuki S, Magara T, Ogasawara H, and Tanaka T (1997) Human butyrylcholinesterase L330I mutation belongs to a fluoride-resistant gene, by expression in human fetal kidney cells. Biochem Biophys Res Commun 240:372-375.
36. Thompson HM (1999) Esterases as markers of exposure to organophosphates and carbamates. Ecotoxicology 8:369-384.
37. von Bernhardi R, Alarcón R, Mezzano D, Fuentes P, and Inestrosa NC (2005) Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 19:204-212.
38. Whittaker M and Britten JJ (1987) E1h, a new allele at cholinesterase locus 1. Hum Hered 37:54-58.
39. Whittaker M and Britten JJ (1988) Recognition of two new phenotypes segregating the E1k allele for plasma cholinesterase. Hum Hered 38:233-239.
40. Yang F, Bian C, Zhu L, Zhao G, Huang Z, and Huang M (2007) Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol 157:348-355.